I welcome an alternative viewpoint, however, you fail to explain your thoughts – allow me to share mine (please do tell me if I am wrong on any points).
Vertex was given via venture philanthropy $75 million. They did not have to dig into their reserves to fund this research and development...
The problem with the NHS? They are viewing Kalydeco as an additional expenditure, not a revolutionary treatment.
The problem with Vertex? GREED, pure and simple GREED.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.